Compare Adaptive Biotechnologies Corp (ADPT) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Gigacloud Technology Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Gigacloud Technology Inc trades at $33.62 (market cap $1.23B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2.7× Gigacloud Technology Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Gigacloud Technology Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | GCT | |
|---|---|---|
Market Cap | $3.33B | $1.23B |
Sector | Health | Technology |
52-Week High | $22.37 | $51.80 |
52-Week Low | $10.24 | $20.26 |
Enterprise Value | $3.19B | $1.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GigaCloud Technology (GCT) trades at $34.08, up 2.62% with a bullish technical signal and strong fundamentals. The stock shows robust earnings beats, with Q1 2026 EPS of $1.04 exceeding expectations by 20%, and maintains healthy profitability with a 10.77% net margin. Recent news highlights inclusion in TIME's World's Growth Leaders 2026 list and positive analyst coverage, supporting investor confidence.
Outlook remains positive due to undervaluation (P/E 8.64), growth in European markets, and strategic expansions. Risks include potential fiduciary concerns flagged by shareholders and reliance on large parcel merchandise demand. Analyst consensus is 66.7% buy, with a $56 price target from Seeking Alpha on 2026-06-10 suggesting 64% upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
